Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish Psoriasis Group* of the Spanish Academy of Dermatology and Venereology;Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis* de la Academia Española de Dermatología y Venereología

Actas Dermo-Sifiliograficas

Volumn 100, Issue 4, 2009, Pages 277-286

  Puig, L ^a   Bordas, X ^b   Carrascosa, J M ^c   Dauden E ^d   Ferrandiz C ^c   Hernanz, J M ^e   Lopez Estebaranz J L ^f   Moreno, J C ^g   Sanchez Carazo J L ^h   Vanaclocha, F ⁱ   Vazquez Veiga H ^j  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^f HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j HOSPITAL DE CONXO   (Spain)

more..

Author keywords

Biologic agents; Consensus; Criteria; Psoriasis; Treatment

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; ISONIAZID; METHOTREXATE;

ALOPECIA; ANOREXIA; ASTHENIA; BONE MARROW SUPPRESSION; CLINICAL EVALUATION; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY SKIN; EVIDENCE BASED PRACTICE; FETUS MALFORMATION; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERMAGNESEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; LIVER TOXICITY; MEDICAL PERSONNEL; MEDICAL SCHOOL; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; PHOTOTHERAPY; PNEUMONIA; PSORIASIS; PUVA; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING; SPAIN; STICKY SKIN; STOMATITIS; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; XEROSIS;

EID: 66249135282     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(09)70821-X     Document Type: Article

References (34)

1. C. Ferrándiz, X. Bordas, V. García-Patos, S. Puig, R. Pujol, and A. Smandía Prevalence of psoriasis in Spain (Epiderma Project: phase I) J Eur Acad Dermatol Venereol 15 2001 20 23 (Pubitemid 32842768)
2. S.R. Rapp, S.R. Feldman, M.L. Exum, A.B. Fleischer Jr, and D.M. Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 1999 401 407 (Pubitemid 29418506)
3. J.M. Gelfand, D.D. Gladman, P.J. Mease, N. Smith, D.J. Margolis, and T. Nijsten Epidemiology of psoriatic arthritis in the population of the United States J Am Acad Dermatol 53 2005 573
4. A. García-Díez, C. Ferrándiz-Foraster, F. Vanaclocha-Sebastián, L. Lizán-Tudela, X. Badia-Llach, and G. Sellers-Fernández What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region Dermatology 216 2008 137 151
5. A.B. Kimball, D. Gladman, J.M. Gelfand, K. Gordon, E.J. Horn, N.J. Korman For the National Psoriasis Foundation National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening J Am Acad Dermatol 58 2008 1031 1042
6. J.M. Gelfand, A.B. Troxel, J.D. Lewis, S.K. Kurd, D.B. Shin, and X. Wang The risk of mortality in patients with psoriasis: results from a population-based study Arch Dermatol 143 2007 1493 1499 (Pubitemid 350277763)
7. R.S. Stern, T. Nijsten, S.R. Feldman, D.J. Margolis, and T. Rolstad Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction J Investig Dermatol Symp Proc 9 2004 136 139 (Pubitemid 38457271)
8. L. Puig-Sanz La psoriasis, ¿una enfermedad sistémica? Actas Dermosifiliogr 98 2007 396 402 (Pubitemid 47251517)
9. J.P. Callen, G.G. Krueger, M. Lebwohl, E.I. McBurney, P. Mease, and A. Menter A.AD.AAD consensus statement on psoriasis therapies J Am Acad Dermatol 49 2003 897 899 (Pubitemid 37314880)
10. S.R. Feldman A quantitative definition of severe psoriasis for use in clinical trials J Dermatolog Treat 15 2004 27 29 (Pubitemid 38252092)
11. J. Schmitt, and G. Wozel The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis Dermatology 210 2005 194 199 (Pubitemid 40529233)
12. A.Y. Finlay Current severe psoriasis and the Rule of Tens Br J Dermatol 152 2005 861 867 (Pubitemid 40704922)
13. C. Ferrándiz Foraster, A. García-Díez, L. Lizán Tudela, L. Bermúdez-Rey, and X. Badia Llach Impacto de la psoriasis en la calidad de vida relacionada con la salud Med Clin (Barc) 128 2007 325 329 (Pubitemid 46587199)
14. D.M. Pariser, J. Bagel, J.M. Gelfand, N.J. Korman, C.T. Ritchlin, B.E. Strober National Psoriasis Foundation National Psoriasis Foundation clinical consensus on disease severity Arch Dermatol 143 2007 239 242 (Pubitemid 46294591)
15. M. Augustin, K. Krüger, M.A. Radtke, I. Schwippl, and K. Reich Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany Dermatology 216 2008 366 372
16. K. Reich, and U. Mrowietz Treatment goals in psoriasis J Dtsch Dermatol Ges 5 2007 566 574 (Pubitemid 47047228)
17. Y. Hongbo, C.L. Thomas, M.A. Harrison, M.S. Salek, and A.Y. Finlay Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 125 2005 659 664
18. A. Leon, A. Nguyen, J. Letsinger, and J. Koo An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options Expert Opin Pharmacother 8 2007 617 632 (Pubitemid 46547015)
19. K.B. Gordon, S.R. Feldman, J.Y. Koo, A. Menter, T. Rolstad, and G. Krueger Definitions of measures of effect duration for psoriasis treatments Arch Dermatol 141 2005 82 84 (Pubitemid 40144447)
20. A. Menter, and C.E. Griffiths Current and future management of psoriasis Lancet 370 2007 272 284 (Pubitemid 47071926)
21. V. Rodríguez-Valverde, R. Cáliz Cáliz, J.M. Álvaro-Gracia Álvaro, J.M. Marenco de la Fuente, J. Mulero Mendoza, and J. Tornero Molina III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la arthritis reumatoide Reumatol Clin 2 Supl 2 2006 S52 S59
22. P.I. Spuls, L. Witkamp, P.M. Bossuyt, and J.D. Bos A systematic review of five systemic treatments for severe psoriasis Br J Dermatol 137 1997 943 949 (Pubitemid 28011136)
23. V.M. Heydendael, P.I. Spuls, B.C. Opmeer, C.A. de Borgie, J.B. Reitsma, and W.F. Goldschmidt Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665 (Pubitemid 36975998)
24. I. Flytström, B. Stenberg, A. Svensson, and I.M. Bergbrant Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial Br J Dermatol 158 2008 116 121 (Pubitemid 350221914)
25. R. Gamo, and J.L. López-Estebaranz Terapia biológica y psoriasis Actas Dermosifiliogr 97 2006 1 17
26. A. Nast, I.B. Kopp, M. Augustin, K.B. Banditt, W.H. Boehncke, and M. Follmann Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris J Dtsch Dermatol Ges 5 Suppl 3 2007 1 119
27. R.G. Langley, V. Ho, C. Lynde, K.A. Papp, Y. Poulin, and N. Shear Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches J Cutan Med Surg 9 Suppl 1 2006 18 25
28. R.G. Langley, and K.B. Gordon Duration of remission of biologic agents for chronic plaque psoriasis J Drugs Dermatol 6 2007 1205 1212
29. A.K. Brimhall, L.N. King, J.C. Licciardone, H. Jacobe, and A. Menter Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Br J Dermatol 159 2008 274 285
30. J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, J.P. Ortonne CHAMPION Study Investigators Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
31. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115 (Pubitemid 350298146)
32. K. Gordon, S. Tyring, Y. Gu, and M. Okun P2654. Psoriasis patients treated continuously with adalimumab: efficacy and safety results from months 12 to 18 J Am Acad Dermatol 58 2008 AB129
33. P.C. Van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, and A. Kaszuba Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension Br J Dermatol 159 2008 1177 1185
34. M. Lebwohl, J. Bagel, J.M. Gelfand, D. Gladman, K.B. Gordon, and S. Hsu From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis J Am Acad Dermatol 58 2008 94 105 (Pubitemid 350302037)